Co-infection Archives

Professor Chen Yaokai: Factors Affecting the Prognosis of HIV Patients with Talaromyces Marneffei Co-Infection Treated with Amphotericin B Deoxycholate

By Mourabit Halima 2023.12.08

Talaromyces marneffei (TM) is a thermal dimorphic fungus that can cause systemic fungal infections in humans. This fungal infection is common in immunocompromised individuals and is one of the leading causes of death among HIV/AIDS patients in Southeast Asia and South Asia. At the 19th European AIDS Conference (EACS) held from October 18 to 21, 2023, Professor Chen Yaokai and his team from the Chongqing Public Health Medical Treatment Center presented a research report titled "Severe Anemia, Severe Leukopenia, and Severe Thrombocytopenia in HIV-Related Talaromyces Marneffei Infection Induced by Amphotericin B Deoxycholate: A Secondary Analysis of a Prospective Multicenter Cohort Study." This study contributes to global efforts to combat the HIV epidemic and co-infections by presenting findings from China. Below is a summary of their research.

IDweek2023 | Hepatitis B Reactivation in HIV Patients: A Comprehensive Study of Antiretroviral Therapy’s Role

By Peter W. PENG 2023.10.27

IDweek2023 Hepatitis B Reactivation in HIV Patients: A Comprehensive Study of Antiretroviral Therapy's Role Hepatitis B, a viral infection that primarily affects the liver, can lead to serious complications, such as cirrhosis and hepatocellular carcinoma. In individuals living with HIV, the situation is further complicated since they face the risk of Hepatitis B reactivation - a condition that can occur when switching to antiretroviral therapy (ART) lacking Hepatitis B activity. This comprehensive article explores this complex medical phenomenon, providing a detailed understanding of its causative factors, implications, and potential strategies for patient management.

IAS 2023 | Short-course tuberculosis (TB) preventive treatment does not affect the virologic efficacy of INSTIs in treating HIV

By Peter W. PENG 2023.10.22

People Living With HIV (PLWH) are at high risk of active tuberculosis (TB). Guidelines both domestically and internationally suggest that PLWH with positive latent tuberculosis infection (LTBI) screening and those with a history of close contact with active TB should receive TB preventive treatment. However, commonly used preventive treatment regimens such as rifampin and rifapentine have potential drug interactions with HIV antiretroviral therapy (ART). A multi-center retrospective study from Taiwan, China, presented at the 12th International AIDS Society HIV Science Conference (IAS 2023) showed that ART based on integrase inhibitors (INSTIs) combined with rifapentine-based short-course TB preventive treatment does not affect the patient's sustained HIV virologic suppression rate.

IAS 2023 | What are the sequelae of MPOX? Does HIV increase the risk of hospitalization due to MPOX?

By Peter W. PENG 2023.10.22

The 12th International AIDS Association HIV Science Conference (IAS 2023) was held in Brisbane, Australia from July 23 to 26, 2023. In the oral reports of the conference, experts from the World Health Organization (WHO) reported that global monitoring data for MPOX in 2022 showed that half of the patients with MPOX were HIV carriers. However, HIV is not a risk factor for increased hospitalization due to MPOX. Another study based on interviews with MPOX patients in Australia indicated that most patients had negative experiences with the disease and sequelae related to MPOX.

Dr. Ana Hoxha: Clinical characteristics and outcomes of MPXV and HIV co-infected patients

By Peter W. PENG 2023.10.22

In 2022, about 70 countries/regions around the world reported cases of MPOX. These countries/regions usually have no prior history of MPXV infections, and previous sustained human-to-human transmissions of MPXV were mainly observed in Africa. At the recent 12th International AIDS Society HIV Science Conference (IAS 2023), Dr. Ana Hoxha from the World Health Organization (WHO) presented a special report titled "HIV among MPOX cases: clinical characteristics and outcomes in the WHO global surveillance 2022".